334 Aidisheng Road
Zhangjiang High-tech Park
33 articles about Viva Biotech
Viva Biotech's Portfolio Company Dogma Therapeutics Reached the Acquisition Agreement with AstraZeneca on Dogma's Oral PCSK9 Inhibitor Program
Dogma Therapeutics ("Dogma"), a Viva Biotech Portfolio Company, has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca. Dogma will receive upfront as well as downstream payments linked to global regulatory and commercial milestones. The pursuit of a convenient, oral PCSK9-based therapy has bee
Revenue Grew by 39% YOY Adjusted Net Profit Rose by 25% YOY Backlog Amount Surged by Approximately 138.2% with Proactive Construction of Comprehensive One-Stop Drug Servicing Platform
Viva Biotech and Langhua Pharmaceutical Reached the Strategic Acquisition Agreement, Accelerating the Escalation of the Service Chain of Innovative Drug Industry
On August 9th, 2020, Viva Biotech Co., Ltd. entered into the Share Purchase Agreement pursuant to which Viva Biotech agreed to acquire and the Vendors agreed to collectively sell 80% of the equity interest in Zhejiang Langhua Pharmaceutical Co., Ltd, at the Consideration of RMB 2,560 million.
Harbour BioMed Announces Strategic Partnership with Viva Biotech to Collaborate on Incubating Innovative Biotech Start-ups
Harbour BioMed, a global clinical stage biopharmaceutical company and Viva Biotech Ltd., a world-leading structure-based drug discovery platform announced a strategic partnership under which both parties will collate their respective expertise in drug discovery and development to promote the incubation of innovative biotech startups.
Viva Biotech and Schrödinger Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets
Viva Biotech Holdings (1873.HK) and Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic collaboration to expand the reach of structure-based drug discovery by generating de novo crystal structures of high-value ta
Schrödinger and Viva Biotech Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets
Collaboration aims to enable discovery of first-in-class therapeutic candidates
On 11 June 2020, Viva BioInnovator successfully held its 1st Demo Day e-congress.
Viva Biotech Holdings announced its annual results for the twelve months ended 31 December 2019.
The 'Future Healthcare VB 100 Summit' organized by VCBeat and VCBeat Research was held in Beijing.
Mebias Discovery Raises $3.5 Million to Expand Pipeline Using a Novel, Cell Signaling-Pathway Selective GPCR Drug Discovery Platform
Development Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects
Two Engine Driven Business Model Fueling Steady Full-range Growth in Business
A list of the top 10 biotech IPOs from January to the end of June this year shows significant involvement in the Hong Stock exchange, with five companies based in China, and one, Frontage Holdings, operating in both the U.S. and China.
Viva Biotech And HQL Pharmaceuticals Join Forces To Form Powerhouse For Structure - And Fragment - Based Drug Discovery